While it is not standard of care to give trastuzumab in combination with radiation therapy in locally advanced HER2+ breast cancer, this manuscript outlines the important relationship between HER2 and radiation sensitivity, which can be used to benefit patients with chest-wall or locoregional recurrences, oligometastatic disease and brain metastases. Here, ERBB2 is linked to breast carcinoma.